1,215 results on '"Riganti, Chiara"'
Search Results
2. Targeting pentamidine towards CD44-overexpressing cells using hyaluronated lipid-polymer hybrid nanoparticles
3. Blood-brain barrier permeability increases with the differentiation of glioblastoma cells in vitro
4. Correction: TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer
5. TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer
6. MiR-155 deficiency and hypoxia results in metabolism switch in the leukemic B-cells
7. RICTOR/mTORC2 downregulation in BRAFV600E melanoma cells promotes resistance to BRAF/MEK inhibition
8. Abstract 4143938: Transcription Factor EB (TFEB) Regulates Metabolic Exchange Between Cardiomyocytes and Epicardial Cells
9. An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA
10. Development of targeted lipid nanoparticles for the combined therapy of triple negative breast cancer: Can curcumin and 6-aminoflavone promote doxorubicin in vitro efficacy?
11. Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy
12. Hypoxia as a critical player in extracellular vesicles-mediated intercellular communication between tumor cells and their surrounding microenvironment
13. Smart hyaluronated micelles to enhance a gemcitabine prodrug efficacy
14. Cytotoxic pathways activated by multifunctional thiosemicarbazones targeting sigma-2 receptors in breast and lung carcinoma cells
15. A novel combinatory treatment against a CDDP-resistant non-small cell lung cancer based on a Ruthenium(II)-cyclopentadienyl compound
16. The highly selective and oral phosphoinositide 3-kinase delta (PI3K-δ) inhibitor roginolisib induces apoptosis in mesothelioma cells and increases immune effector cell composition
17. Enhancing pancreatic ductal adenocarcinoma (PDAC) therapy with targeted carbon nano-onion (CNO)-mediated delivery of gemcitabine (GEM)-derived prodrugs
18. p140Cap modulates the mevalonate pathway decreasing cell migration and enhancing drug sensitivity in breast cancer cells
19. Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia
20. Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: New potent P-gp modulators acting as MDR reversers
21. Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
22. The role of Extracellular Vesicles in glycolytic and lipid metabolic reprogramming of cancer cells: Consequences for drug resistance
23. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death
24. TFEB controls integrin-mediated endothelial cell adhesion by the regulation of cholesterol metabolism
25. Mitochondria Transplantation Mitigates Damage in an In Vitro Model of Renal Tubular Injury and in an Ex Vivo Model of DCD Renal Transplantation
26. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)
27. Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
28. First-In-Class Thiosemicarbazone Metal Complexes Targeting the Sigma‑2 Receptor (S2R) as an Innovative Strategy against Pancreatic Cancer.
29. Sdox, a H2S releasing anthracycline, with a safer profile than doxorubicin toward vasculature
30. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro
31. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma
32. Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer
33. Changes of physico-chemical properties of nano-biomaterials by digestion fluids affect the physiological properties of epithelial intestinal cells and barrier models
34. Impact of cancer metabolism on therapy resistance – Clinical implications
35. Hypoxia as a driver of resistance to immunotherapy
36. Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models
37. The heme synthesis-export system regulates the tricarboxylic acid cycle flux and oxidative phosphorylation
38. Tuning NO release of organelle-targeted furoxan derivatives and their cytotoxicity against lung cancer cells
39. Joining European Scientific Forces to Face Pandemics
40. Abstract 12168: Pi3kγ is a Key Modulator of Cardiac Metabolism Rewiring Occurring in Doxorubicin-Treated Mice
41. Impedance-based drug-resistance characterization of colon cancer cells through real-time cell culture monitoring
42. One molecule two goals: A selective P-glycoprotein modulator increases drug transport across gastro-intestinal barrier and recovers doxorubicin toxicity in multidrug resistant cancer cells
43. Cholesterol metabolism: At the cross road between cancer cells and immune environment
44. MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells
45. Synthesis of defined oligohyaluronates-decorated liposomes and interaction with lung cancer cells
46. In vitro vascular toxicity assessment of NitDOX, a novel NO-releasing doxorubicin
47. From mitochondria to healthy aging: The role of branched-chain amino acids treatment: MATeR a randomized study
48. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
49. Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R)
50. Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.